Abacavir and metabolite pharmacokinetics in HIV-1-infected children and adolescents. - Wikidata - wikimedia - TriplyDB

Abacavir and metabolite pharmacokinetics in HIV-1-infected children and adolescents.

Abacavir and metabolite pharmacokinetics in HIV-1-infected children and adolescents.

http://www.wikidata.org/entity/Q33720839

about

Population pharmacokinetics of abacavir in infants, toddlers and children.Pharmacotherapy of pediatric and adolescent HIV infection Abacavir pharmacokinetics during chronic therapy in HIV-1-infected adolescents and young adults.Pharmacokinetic optimization of antiretroviral therapy in children and adolescents.Molecular recognition of the antiretroviral drug abacavir: towards the development of a novel carbazole-based fluorosensor

P2860

Q36948138-8FE6D93B-DA17-4E34-A885-196EBF01357F Q37240305-1DB04D93-5F4B-464A-AD65-145C13881EC2 Q37399199-402B3B10-F1A7-488E-B820-83AE9297BD0B Q37835819-63700D0C-54A6-4DE9-9B5C-B93DDDA09BCE Q42769588-42030BF5-E504-4B23-816E-1AE65DD98113

P2860

Abacavir and metabolite pharmacokinetics in HIV-1-infected children and adolescents.

http://www.wikidata.org/entity/Q33720839

description

2009 nî lūn-bûn

@nan

2009 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Abacavir and metabolite pharmacokinetics in HIV-1-infected children and adolescents.

@ast

Abacavir and metabolite pharmacokinetics in HIV-1-infected children and adolescents.

@en

type

label

Abacavir and metabolite pharmacokinetics in HIV-1-infected children and adolescents.

@ast

Abacavir and metabolite pharmacokinetics in HIV-1-infected children and adolescents.

@en

prefLabel

Abacavir and metabolite pharmacokinetics in HIV-1-infected children and adolescents.

@ast

Abacavir and metabolite pharmacokinetics in HIV-1-infected children and adolescents.

@en

P1433

Q33720839-9D99D1BE-8948-4512-BF2E-ECB37A18C21B

P1476

Q33720839-303863AA-109E-482D-8FE3-7F0B741FA0DD

P2093

Q33720839-0DD2596F-506D-4181-8B20-61CF55F96E8C

Q33720839-6CF9BAE0-8169-4BF2-A045-CD96E42D637F

Q33720839-8C6D8182-7266-4C76-A205-41C5E4F91C04

Q33720839-A38566CF-D6DD-4B2E-B49D-06D0BB8FA5E0

Q33720839-AA9A0692-8398-4EFB-9DB4-4C1211575709

Q33720839-B2CE4FD9-B39C-485F-9C29-9E24695090B5

Q33720839-EDA6CC68-DCBC-46E8-9BC3-9971FF9C20A3

P2860

Q33720839-227910DF-37CC-4356-A30A-E22A9AFAE09D

Q33720839-284A8BB4-5F29-4FE5-AEB2-53C29B47BAAD

Q33720839-288F7EBD-7DD5-4F52-A672-23C9CF845348

Q33720839-3CCE3BB7-5C25-4806-B2A4-4C588DE14183

Q33720839-48E392AA-1396-4570-B2AA-99366E6414A7

Q33720839-5531E793-B59C-4378-9F89-03637A67333C

Q33720839-651CE78A-BDDA-4BE7-BBDC-64BA958B7CAC

Q33720839-777E2513-27EE-4EFA-B469-DF620DA2F383

Q33720839-A09B4272-6ACD-4368-95A1-4586374EB051

Q33720839-ADDC5662-4FE9-4652-908E-3A8D66CB4933

P304

Q33720839-D7D39BDD-E741-4A1F-8814-CE9AC68B77BD

P31

Q33720839-8D92832F-59CD-46F3-B147-1379714F2DE7

P356

Q33720839-C321010F-755A-4B3C-8403-6F7973D99684

P407

Q33720839-5A3F6909-7D73-4EC5-B25E-6CCE14C7730F

P433

Q33720839-F6359E0C-128D-42F8-BFE5-8C79B77B7DD3

P478

Q33720839-76EB9E8A-7833-4DC4-BD09-D45C6DA5407D

P577

Q33720839-8789F5EE-E89C-42C6-BBC0-8D48F57FDE5F

P698

Q33720839-F1904E03-7CD5-4A58-94DE-F8AF93D3E207

P932

Q33720839-94B29747-3641-418B-B358-1B7FFF41F76E

P356

QAI.0B013E31819A2257

P1433

Journal of Acquired Immune Deficiency Syndromes

P1476

Abacavir and metabolite pharmacokinetics in HIV-1-infected children and adolescents.

@en

P2093

Brian L Robbins

http://www.w3.org/2001/XMLSchema#string

Charles H Rose

http://www.w3.org/2001/XMLSchema#string

Geoffrey J Yuen

http://www.w3.org/2001/XMLSchema#string

Jane C Lindsey

http://www.w3.org/2001/XMLSchema#string

John H Rodman

http://www.w3.org/2001/XMLSchema#string

Lawrence J D'angelo

http://www.w3.org/2001/XMLSchema#string

Shane J Cross

http://www.w3.org/2001/XMLSchema#string

P2860

Unique intracellular activation of the potent anti-human immunodeficiency virus agent 1592U89

Genetic polymorphism of UDP-glucuronosyltransferase 2B7 (UGT2B7) at amino acid 268: ethnic diversity of alleles and potential clinical significance

Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: A randomized equivalence trial.

Safety and pharmacokinetics of abacavir (1592U89) following oral administration of escalating single doses in human immunodeficiency virus type 1-infected adults

Safety and single-dose pharmacokinetics of abacavir (1592U89) in human immunodeficiency virus type 1-infected children.

Single-dose pharmacokinetics and safety of abacavir (1592U89), zidovudine, and lamivudine administered alone and in combination in adults with human immunodeficiency virus infection

Population pharmacokinetics and pharmacodynamic modeling of abacavir (1592U89) from a dose-ranging, double-blind, randomized monotherapy trial with human immunodeficiency virus-infected subjects.

Multiple-dose pharmacokinetics and pharmacodynamics of abacavir alone and in combination with zidovudine in human immunodeficiency virus-infected adults.

The role of hepatic and extrahepatic UDP-glucuronosyltransferases in human drug metabolism.

Genetic polymorphisms of UDP-glucuronosyltransferases and their functional significance.

P304

54-59

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/QAI.0B013E31819A2257

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

51

http://www.w3.org/2001/XMLSchema#string

P577

2009-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19282779

http://www.w3.org/2001/XMLSchema#string

P932

2836884

http://www.w3.org/2001/XMLSchema#string